Lipoprotein changes in patients with chronic hepatitis C treated with interferon-alpha
| Autor: | Natalia Schöebel, Sagrario Larumbe, Consuelo Fernández-Miranda, Teresa Gómez-Izquierdo, Gregorio Castellano, Carlos Guijarro, Angel del Palacio, Inmaculada Fernández |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
Adult
Male medicine.medical_specialty Very low-density lipoprotein Time Factors Hepatitis C virus Lipoproteins Alpha interferon Interferon alpha-2 medicine.disease_cause Gastroenterology Antiviral Agents chemistry.chemical_compound High-density lipoprotein Internal medicine medicine Humans Prospective Studies Interferon alfa Hypertriglyceridemia Hepatology medicine.diagnostic_test business.industry nutritional and metabolic diseases Interferon-alpha Hepatitis C Chronic Recombinant Proteins chemistry Low-density lipoprotein Immunology lipids (amino acids peptides and proteins) Female Lipid profile business medicine.drug Lipoprotein |
| Zdroj: | The American journal of gastroenterology. 93(10) |
| ISSN: | 0002-9270 |
| Popis: | Objective: The aim of this study was to evaluate the effects of interferon-α therapy on the lipid profile of patients with chronic hepatitis C. Methods: In 36 consecutive patients with chronic hepatitis C, fasting lipoproteins were evaluated prospectively at baseline, 1, 3 and 6 months during interferon-α therapy and 3 months after the end of treatment. Results: During interferon-α therapy, there was a progressive increase in total and very low density lipoprotein (VLDL)-triglycerides, VLDL-cholesterol and a sustained raise in apolipoprotein (apo) B. In parallel, there was a reduction in high density lipoprotein (HDL)-cholesterol and apo A1 levels. In contrast, total and low density lipoprotein (LDL)-cholesterol and lipoprotein (a) levels remained essentially unchanged during interferon-α therapy. Three patients developed chylomicronemia, two of them with severe hypertriglyceridemia, although none of them presented with pancreatitis. Chylomicronemia and severe hypertriglyceridemia were more common in patients with basal triglycerides above 200 mg/dl. Nineteen patients responded to interferon-α therapy, but their lipid profile did nor differ from that of nonresponders. Three months after the end of interferon-α therapy lipid changes subsided, although VLDL and HDL-cholesterol and apo B did not reach basal levels. Conclusion: In patients with chronic hepatitis C, interferon-α therapy is associated with an increase of total and VLDL-triglycerides, VLDL-cholesterol and apo B, and a decline of HDL-cholesterol and apo A1. The development of chylomicronemia and severe hypertriglyceridemia in some cases makes mandatory a close monitoring of triglycerides during interferon-α therapy, particularly among patients with increased triglycerides at baseline. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|